Back to Hematology
Hematologyv2018Evidence-Based

Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage

Calculates amount of RhIG (RhoGAM) to be administered to Rh-negative mother following maternal-fetal hemorrhage to prevent hemolytic disease of the fetus and newborn (HDFN). Essential for preventing maternal anti-D antibody formation when Rh-negative mother is exposed to Rh-positive fetal blood.

Clinical Input Parameters

mL
Range: 2000 — 6000 mL
%
Range: 0 — 10 %
Clinical Assessment
Awaiting Parameters
rhig dosage
—vials
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Number of RhIG vials (300 μg) = (fetal_cell_percentage / 100) × maternal_blood_volume (mL) / 30 mL, rounded to nearest whole number + 1 additional vial for safety margin

Clinical Pearls & Practice Notes

  • Standard 300 μg dose protects against 30 mL of fetal whole blood (15 mL of fetal red cells)
  • Before 12 weeks gestation, mini-dose of 150 μg may be used (protects against 2.5 mL fetal RBCs)
  • After 12 weeks gestation, full 300 μg dose is recommended
  • Isoimmunization can occur with as little as 0.01-0.03 mL of fetal-maternal hemorrhage
  • Rounding rules: if decimal <0.5, round up to next whole number; if ≥0.5, round up and add 1
  • Flow cytometry is more accurate than Kleihauer-Betke test for fetal cell quantification
  • Maternal blood volume can be estimated via Nadler's formula: 0.3561 × height³(m) + 0.03308 × weight(kg) + 0.1833 L
  • Normal baseline fetal cell percentage is <0.1% in maternal circulation
  • Clinical significance typically begins at >0.3% fetal cells
  • RhIG should be administered within 72 hours of delivery for optimal efficacy
  • May be effective up to 28 days post-exposure but efficacy decreases with time
  • Monitor for signs of maternal alloimmunization with subsequent pregnancies
  • Consider follow-up testing to confirm adequate suppression of anti-D formation

Evidence & Literature Citations

  1. AABB Technical Manual, 18th edition. American Association of Blood Banks; 2014.
  2. American College of Obstetricians and Gynecologists. Prevention of Rh D alloimmunization. ACOG Practice Bulletin No. 4. Washington, DC: American College of Obstetricians and Gynecologists; 1999.
  3. Bowman JM. The prevention of Rh immunization. Transfus Med Rev. 1988;2(3):129-50. doi: 10.1016/s0887-7963(88)70067-9.
  4. Queenan JT, Tomai TP, Ural SH, King JC. Deviation in amniotic fluid optical density at a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks' gestation: a proposal for clinical management. Am J Obstet Gynecol. 1993;168(5):1370-6. doi: 10.1016/0002-9378(93)90384-k.

Score Interpretation Ranges

Standard Dose1 – 1 pts

Minimal maternal-fetal hemorrhage

Moderate Hemorrhage2 – 3 pts

Moderate maternal-fetal hemorrhage

Large Hemorrhage4 – 10 pts

Large maternal-fetal hemorrhage

Massive Hemorrhage11 – 50 pts

Massive maternal-fetal hemorrhage

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.